A transdermal administration device includes: a substrate having a first surface and a second surface opposite to the first surface; a plurality of projections protruding from the first surface of the substrate, the plurality of projections being provided for piercing an administration target; and a raised and/or recessed structure composed of a plurality of raised and/or recessed elements. The plurality of raised and/or recessed elements includes at least either of raised elements raised from the second surface or recessed elements recessed from the second surface. The substrate, the projections and the raised and/or recessed structure are made of transparent material, and the plurality of raised and/or recessed elements forms a pattern as viewed in a direction perpendicular to the second surface which is finer than a pattern formed by the plurality of projections as viewed in a direction perpendicular to the first surface.

A transdermal patch comprising (2R,6R)-hydroxynorketamine or a conjugate thereof. The active agent may be in its free base form. The transdermal patch may comprise a drug-containing layer comprising the active agent and a carrier material. The transdermal patch may comprise an adhesive. Examples of adhesive materials that could be used include pressure-sensitive acrylic adhesives, pressure-sensitive silicone adhesives, or other type of pressure-sensitive adhesive.

A transdermal dosing unit may include a first segment having a first pharmaceutical in a first reservoir, a first releasing compound, and a first adhesive component, a second segment removably connected to the first segment, the second segment having a second pharmaceutical in a second reservoir, a second releasing component, and a second adhesive component, and a backing component. The transdermal dosing unit may further include additional segments, and may include a perforated section between each segment. The first adhesive component may have a first adhesion strength, and the second adhesive component may have a second adhesion strength that is either different from or approximately equal to the first adhesion strength. A method of titrating a dose of such a transdermal dosing unit may include applying the transdermal dosing unit to a subject, and removing the first segment while leaving the second segment on the subject.

Transdermal therapeutic system and method of using the same for safely treating hypocholinergic disorders of the central nervous system such as Alzheimer type dementia. The transdermal therapeutic system comprises oxybutynin in combination with a cholinergic receptor agonist (CRA) such as xanomeline.

A transdermal delivery system for systemic delivery of donepezil is described, where the system comprises an adhesive matrix drug reservoir layer comprised of a copolymer of acrylic acid/vinyl acetate, triethyl citrate, and donepezil base generated in situ by reaction of donepezil HCl and an alkaline salt. The system is provided for treatment of Alzheimer's disease, and achieves transdermal delivery of the therapeutic agent at steady state that is bioequivalent to administration of the therapeutic agent orally.

Compositions, devices, and methods for transdermal administration of active agents provided in their salt form instead of neutral form are provided.

A transdermal delivery system for systemic delivery of donepezil is described, where the system comprises an adhesive matrix drug reservoir layer comprised of a copolymer of acrylic acid/vinyl acetate, triethyl citrate, and donepezil base generated in situ by reaction of donepezil HCl and an alkaline salt. The system is provided for treatment of Alzheimer's disease, and achieves transdermal delivery of the therapeutic agent at steady state that is bioequivalent to administration of the therapeutic agent orally.

Compositions, devices, and methods for transdermal administration of active agents provided in their salt form instead of neutral form are provided.

Transdermal delivery systems for the systemic delivery of memantine are described, wherein the system comprises a drug reservoir layer and an adhesive layer, optionally together with one or more intermediate and/or supporting layers, wherein the drug reservoir layer comprises an acrylate polymer or copolymer, a permeation enhancer, a carrier, and memantine base generated in situ by reaction of a memantine salt and an alkaline salt. Compositions and kits comprising the various components, e.g., drug reservoir and/or adhesive compositions are described. Methods relating to treatment of CNS disorders, e.g., Alzheimer's disease and/or dementia, using the aforementioned transdermal delivery devices and/or compositions are also described.

A method for delivering a therapeutic agent to a subject from a transdermal delivery system is described, where the therapeutic agent (i) has a half-life in the blood when delivered orally of greater than about 48 hours and (ii) is for the treatment of a chronic condition. The transdermal delivery system achieves transdermal delivery of the therapeutic agent at steady state that is bioequivalent to administration of the therapeutic agent orally, wherein bioequivalency is established by (a) a 90% confidence interval of the relative mean Cmax and AUC of the therapeutic agent administered from the transdermal delivery system and via oral delivery between 0.70 and 1.43 or between 0.80 and 1.25, or (b) a 90% confidence interval of the ratios for AUC and Cmax of the therapeutic agent administered from the transdermal delivery system and via oral delivery between 0.70 and 1.43 or between 0.80 and 1.25.